{
    "clinical_study": {
        "@rank": "168025", 
        "arm_group": [
            {
                "arm_group_label": "PVX-410,  .4 mg dose", 
                "arm_group_type": "Experimental", 
                "description": "Approximately 3  patients will receive 6, bi-weekly, subcutaneous injections of a .4 mg dose of PVX-410 in combination with an intramuscular injection of Hiltonol (poly ICLC).  Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months."
            }, 
            {
                "arm_group_label": "PVX-410,  .8 mg dose", 
                "arm_group_type": "Experimental", 
                "description": "Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of an .8 mg dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC).  Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months."
            }, 
            {
                "arm_group_label": "PVX-410 plus lenalidomide", 
                "arm_group_type": "Experimental", 
                "description": "Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of an .8 mg dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will also receive 3 cycles of lenalidomide. Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety and tolerability of PVX-410, (a cancer\n      vaccine), treatment regimen for patients with smoldering multiple myeloma as a single agent\n      and in combination with lenalidomide."
        }, 
        "brief_title": "Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Smoldering Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a dose escalation, phase 1/2a study to assess the safety and tolerability of\n      PVX-410, (a multi-peptide cancer vaccine), treatment regimen in patients with smoldering\n      multiple myeloma as a single agent and in combination with lenalidomide..  Approximately 22\n      patients will receive six (6) bi-weekly, subcutaneous injections of PVX-410 for a total of\n      twelve (12) weeks of treatment.  Safety will be monitored throughout the study.\n      Tolerability, immunogenicity and clinical response will also be measured as described in the\n      protocol."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  Patient has confirmed clinical diagnosis of SMM according to a definition derived\n             from the International Myeloma Working Group (IMWG) definition:  serum M-protein \u22653\n             g/dL or bone marrow clonal plasma cells (BMPC) >10%, or both, along with normal organ\n             and marrow function (CRAB) within 4 weeks before baseline.\n\n          -  C:  Absence of hypercalcemia, evidenced by a calcium <10.5 mg/dL.\n\n          -  R:  Absence of renal failure, evidenced by a creatinine <2.0 mg/dL or calculated\n             creatinine clearance (using the Modification of Diet in Renal Disease [MDRD] formula)\n             >50 mL/min.\n\n          -  A:  Absence of anemia, evidenced by a hemoglobin >10 g/dL.\n\n          -  B:  Absence of lytic bone lesions on standard skeletal survey.\n\n          -  Patient is at higher than average risk of progression to active MM, defined as having\n             2 or more of the following features:\n\n          -  Serum monoclonal (M)-protein \u22653 g/dL.\n\n          -  BMPC >10%.\n\n          -  Abnormal serum free light chain (FLC) ratio (0.26-1.65).\n\n          -  Patient has a life expectancy of greater than 6 months\n\n          -  Patient is human leukocyte antigen (HLA)-A2 positive.\n\n          -  Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or\n             1.\n\n          -  Patient has adequate bone marrow function, evidenced by a platelet count \u226575\u00d7109/L\n             and an absolute neutrophil count (ANC) \u22651.0\u00d7109/L within 2 weeks before baseline.\n\n          -  Patient has adequate hepatic function, evidenced by a bilirubin \u22642.0 mg/dL and an\n             alanine transaminase (ALT), and aspartate transaminase (AST) \u22642.5\u00d7 the upper limit of\n             normal (ULN) within 2 weeks before baseline.\n\n          -  If of child-bearing potential, patient agrees to use adequate birth control measures\n             during study participation.\n\n          -  If a female of child-bearing potential, patient has negative urine pregnancy test\n             results within 2 weeks before baseline and is not lactating.\n\n          -  Patient (or his or her legally accepted representative) has provided written informed\n             consent to participate in the study.\n\n        Exclusion Criteria:\n\n          -  Patient has symptomatic multiple myeloma, as defined by any of the following:\n\n          -  Lytic lesions or pathologic fractures.\n\n          -  Anemia (hemoglobin <10 g/dL).\n\n          -  Hypercalcemia (corrected serum calcium >11.5 mg/dL).\n\n          -  Renal insufficiency (creatinine >2 mg/dL).\n\n          -  Other: symptomatic hyperviscosity, amyloidosis.\n\n          -  Patient has a history of a prior malignancy within the past 5 years (excluding\n             resected basal cell carcinoma of the skin or in situ cervical cancer).\n\n          -  Patient has abnormal cardiac status, evidenced by any of the following:\n\n          -  New York Heart Association (NYHA) stage III or IV congestive heart failure (CHF).\n\n          -  Myocardial infarction within the previous 6 months.\n\n          -  Symptomatic cardiac arrhythmia requiring treatment or persisting despite treatment.\n\n          -  Patient is receiving any other investigational agent.\n\n          -  Patient has a current active infectious disease or positive serology for human\n             immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV).\n\n          -  Patient has a history of or current auto-immune disease.\n\n          -  Patient has been vaccinated with live attenuated vaccines within 4 weeks before study\n             vaccination."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "95 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01718899", 
            "org_study_id": "2010-001"
        }, 
        "intervention": {
            "arm_group_label": [
                "PVX-410,  .4 mg dose", 
                "PVX-410,  .8 mg dose", 
                "PVX-410 plus lenalidomide"
            ], 
            "description": "Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of a dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC).  Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months", 
            "intervention_name": "PVX-410", 
            "intervention_type": "Biological", 
            "other_name": "Revlimid"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "contact": {
                    "email": "Sharon.ingram@emory.edu", 
                    "last_name": "Sharon Curate Ingram", 
                    "phone": "404-778-2164"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30322"
                    }, 
                    "name": "Winship Cancer Institute, Emory University"
                }, 
                "investigator": {
                    "last_name": "Ajay Nooka, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mwilkes@mgh.harvard.edu", 
                    "last_name": "Meredith Wilkes", 
                    "phone": "617-643-3503"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Massachusetts General Hospital"
                }, 
                "investigator": {
                    "last_name": "Noopur Raje, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ArielleE_abovich@dfci.harvard.edu", 
                    "last_name": "Arielle Abovich", 
                    "phone": "617-632-3655"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Dana Farber Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Paul Richardson, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "tlens@bidmc.harvard.edu", 
                    "last_name": "Timothy Lens", 
                    "phone": "617-667-9922"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Beth Israel Deaconess Medical Center"
                }, 
                "investigator": {
                    "last_name": "David Avigan, MD PhD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "arnaig@mdanderson.org", 
                    "last_name": "Adam Naig", 
                    "phone": "713-563-5277"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "University of Texas, MD Anderson Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Michael Wang, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma", 
        "other_outcome": {
            "description": "Clinical response will be determined by the treating physician according to the International Myeloma Working Group Disease Response Criteria.", 
            "measure": "Clinical Response will be measured.", 
            "safety_issue": "No", 
            "time_frame": "Designated timepoints during the treatment phase (3 months) and follow up phase (12 months)"
        }, 
        "overall_official": [
            {
                "affiliation": "Massachusetts General Hospital", 
                "last_name": "Noopur Raje, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "M.D. Anderson Cancer Center", 
                "last_name": "Michael Wang, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Emory University", 
                "last_name": "Ajay Nooka, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "All adverse events will be recorded.", 
            "safety_issue": "Yes", 
            "time_frame": "Throughout treatment phase (3 months) and follow up period (12 months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01718899"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Patient blood samples will be measured for immune response through ELISPOT and Pentamer assays.", 
            "measure": "Immune response to the vaccine will be measured", 
            "safety_issue": "No", 
            "time_frame": "Designated timepoints during the treatment phase (3 months) and follow up phase (12 months)"
        }, 
        "source": "OncoPep, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "OncoPep, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}